Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Self-efficacy for coping with cancer in melanoma patients: its association with physical fatigue and depression.

Albrecht K, Droll H, Giesler JM, Nashan D, Meiss F, Reuter K.

Psychooncology. 2013 Sep;22(9):1972-8. doi: 10.1002/pon.3238. Epub 2013 Jan 3.

PMID:
23288588
2.
3.

Health-related quality of life before and during adjuvant interferon-α treatment for patients with malignant melanoma (DeCOG-trial).

Ziefle S, Egberts F, Heinze S, Volkenandt M, Schmid-Wendtner M, Tilgen W, Linse R, Boettjer J, Vogt T, Spieth K, Eigentler T, Brockmeyer NH, Heinz A, Hauschild A, Schaefer M.

J Immunother. 2011 May;34(4):403-8. doi: 10.1097/CJI.0b013e31821b7a4b.

PMID:
21499123
4.

Health-related quality of life, fatigue, and depression under low-dose IFN-α therapy in melanoma patients.

Reuter K, Albrecht K, Seelig H, Meiss F, Mauch C, Kreuzberg N, Nashan D.

J Immunother. 2014 Nov-Dec;37(9):461-7. doi: 10.1097/CJI.0000000000000057.

PMID:
25304729
5.

Depressive mood changes and psychiatric symptoms during 12-month low-dose interferon-alpha treatment in patients with malignant melanoma: results from the multicenter DeCOG trial.

Heinze S, Egberts F, Rötzer S, Volkenandt M, Tilgen W, Linse R, Boettjer J, Vogt T, Spieth K, Eigentler T, Brockmeyer NH, Hinzpeter A, Hauschild A, Schaefer M.

J Immunother. 2010 Jan;33(1):106-14. doi: 10.1097/CJI.0b013e3181b8bdb9.

PMID:
19952950
6.

Correlation between sICAM-1 and depressive symptoms during adjuvant treatment of melanoma with interferon-alpha.

Schaefer M, Horn M, Schmidt F, Schmid-Wendtner MH, Volkenandt M, Ackenheil M, Mueller N, Schwarz MJ.

Brain Behav Immun. 2004 Nov;18(6):555-62.

PMID:
15331126
7.

Dose-dependent development of depressive symptoms during adjuvant interferon-{alpha} treatment of patients with malignant melanoma.

Friebe A, Horn M, Schmidt F, Janssen G, Schmid-Wendtner MH, Volkenandt M, Hauschild A, Goldsmith CH, Schaefer M.

Psychosomatics. 2010 Nov-Dec;51(6):466-73. doi: 10.1176/appi.psy.51.6.466.

PMID:
21051677
8.

Quality-of-life evaluation in an interferon therapy after radical surgery in cutaneous melanoma patients.

Rataj D, Jankowiak B, Krajewska-Kułak E, Van Damme-Ostapowicz K, Nowecki ZI, Rutkowski P, Niczyporuk W.

Cancer Nurs. 2005 May-Jun;28(3):172-8.

PMID:
15915059
9.

Pretreatment levels of sTNF-R1 and sIL-6R are associated with a higher vulnerability for IFN-alpha-induced depressive symptoms in patients with malignant melanoma.

Friebe A, Schwarz MJ, Schmid-Wendtner M, Volkenandt M, Schmidt F, Horn M, Janssen G, Schaefer M.

J Immunother. 2007 Apr;30(3):333-7.

PMID:
17414324
10.

Role functioning before start of adjuvant treatment was an independent prognostic factor for survival and time to failure. A report from the Nordic adjuvant interferon trial for patients with high-risk melanoma.

Brandberg Y, Johansson H, Aamdal S, Bastholt L, Hernberg M, Stierner U, von der Maase H, Hansson J; Nordic Melanoma Cooperative Group..

Acta Oncol. 2013 Aug;52(6):1086-93. doi: 10.3109/0284186X.2013.789140. Epub 2013 Apr 28.

PMID:
23621752
11.

Longitudinal course of depression, fatigue, and quality of life in patients with high risk melanoma receiving adjuvant interferon.

Trask PC, Paterson AG, Esper P, Pau J, Redman B.

Psychooncology. 2004 Aug;13(8):526-36.

PMID:
15295774
12.

Predictors of quality of life in newly diagnosed melanoma and breast cancer patients.

Lehto US, Ojanen M, Kellokumpu-Lehtinen P.

Ann Oncol. 2005 May;16(5):805-16. Epub 2005 Apr 7.

PMID:
15817599
13.

Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.

Mocellin S, Pasquali S, Rossi CR, Nitti D.

J Natl Cancer Inst. 2010 Apr 7;102(7):493-501. doi: 10.1093/jnci/djq009. Epub 2010 Feb 23. Review.

PMID:
20179267
14.

Self-efficacy and pain catastrophizing in systemic lupus erythematosus: relationship to pain, stiffness, fatigue, and psychological distress.

Somers TJ, Kurakula PC, Criscione-Schreiber L, Keefe FJ, Clowse ME.

Arthritis Care Res (Hoboken). 2012 Sep;64(9):1334-40. doi: 10.1002/acr.21686.

15.
16.

Health-related quality of life in early breast cancer.

Groenvold M.

Dan Med Bull. 2010 Sep;57(9):B4184.

PMID:
20816024
17.

Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.

Hancock BW, Wheatley K, Harris S, Ives N, Harrison G, Horsman JM, Middleton MR, Thatcher N, Lorigan PC, Marsden JR, Burrows L, Gore M.

J Clin Oncol. 2004 Jan 1;22(1):53-61. Epub 2003 Dec 9.

PMID:
14665609
18.

[Sarcoidosis, myasthenia gravis and anterior ischaemic optic neuropathy: severe side effects of adjuvant interferon-alpha-therapy in malignant melanoma?].

Kreutzer K, Bonnekoh B, Franke I, Ulrich J, Gollnick H.

J Dtsch Dermatol Ges. 2004 Aug;2(8):689-94. German.

PMID:
16279234
19.

Fatigue in patients with cancer receiving interferon alpha.

Dean GE, Spears L, Ferrell BR, Quan WD, Groshon S, Mitchell MS.

Cancer Pract. 1995 May-Jun;3(3):164-72.

PMID:
7599673
20.

The role of symptoms and self-efficacy in predicting physical activity change among older adults with arthritis.

Sperber N, Hall KS, Allen K, DeVellis BM, Lewis M, Callahan LF.

J Phys Act Health. 2014 Mar;11(3):528-35. doi: 10.1123/jpah.2012-0030. Epub 2013 Feb 8.

PMID:
23416927

Supplemental Content

Support Center